1. Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
NSCLC, non-small-cell lung cancer.
This activity is supported by educational grants from Amgen, Ariad, Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.

2. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Background
ALK+ and ROS1+ NSCLC pts frequently develop resistance to TKIs through secondary mutations[1,2]
Lorlatinib: novel, broad spectrum, potent ALK and ROS1 inhibitor
Active against multiple mutations conferring resistance to other ALK and ROS1 TKIs, including crizotinib, ceritinib, alectinib[3]
Current report on dose escalation component of ongoing phase I/II study of lorlatinib in advanced ALK+ or ROS1+ NSCLC[4]
NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor.
1. Johnson TW, et al. J Med Chem. 2014;57: Zou HY, et al. Proc Natl Acad Sci U S A. 2015;112: Zou HY, et al. AACR-NCI Abstract A Solomon BJ, et al. ASCO Abstract 9009.
Slide credit: clinicaloptions.com

3. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Study Design
Open-label phase I/II trial
Primary objective: safety/tolerability at increasing dose levels to establish RP2D
Secondary objectives: antitumor activity, PK, pt-reported outcomes, correlative studies
ALK+ or ROS1+ NSCLC;
treatment-naive or PD after ≥ 1 prior
ALK/ROS1 TKI;
≥ 1 measurable extracranial lesion
(N = 54)
Dose Escalation
Lorlatinib
10, 25, 50, 75, 100*, 150, or 200† mg QD Q3W
35, 75, or 100 mg BID Q3W
Tx until PD or unacceptable toxicity
*Chosen as RP2D, n = 17.
†One DLT observed.
DLT, dose-limiting toxicity; NSCLC, non-small-cell lung cancer; PD, progressive disease; PK, pharmacokinetics; RP2D, recommended phase II dose; TKI, tyrosine kinase inhibitor; Tx, treatment.
Slide credit: clinicaloptions.com
Solomon BJ, et al. ASCO Abstract 9009.

4. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Baseline Characteristics
All Pts (N = 54)
Mean age, yrs (SD)
51.9 (12.8)
Female, % 59
Race, %
White/black/Asian/other
78/7/13/2
Brain metastases present, % 72
ALK/ROS1 status, %
ALK+
ROS1+
Not confirmed 76 22 2
Prior no. ALK/ROS1 TKIs, % 1
≥ 2 13 37 50
NSCLC, non-small-cell lung cancer; SD, standard deviation; TKI, tyrosine kinase inhibitor.
Slide credit: clinicaloptions.com
Solomon BJ, et al. ASCO Abstract 9009.

5. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Safety
Treatment-Related AE, %
All LOR Doses (N = 54)
LOR 100 mg QD (n = 17)
Any
Gr 3/4 93 30 94 29
Causing dose delay 33 20
24*
18*
Causing dose reduction 24 9
Hypercholesterolemia 69 11 82 12
Peripheral edema 37 53
Hypertriglyceridemia 6 41
Peripheral neuropathy 22 NR
Fatigue 15
Slow speech 18
AE, adverse event; Gr, grade; LOR, lorlatinib; NR, not reported; NSCLC, non-small-cell lung cancer.
*Most frequently because of hypercholesterolemia.
Slide credit: clinicaloptions.com
Solomon BJ, et al. ASCO Abstract 9009.

6. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Efficacy I
Response
1 Prior ALK TKI (n = 14)
≥ 2 Prior ALK TKIs (n = 26)
Total ALK+
(n = 41)
ORR, % (95% CI)
57 (29-82)
42 (23-63)
46 (31-63)
Best overall response, % CR PR
Unconfirmed PR SD PD
Indeterminate 7 50 21 14 8 35 4 19 27 39 2 20 24
Median PFS, mos (95% CI)
13.5 (1.6-NR)
9.2 (1.5-NR)
11.4 ( )
12-mo PFS, % (95% CI)
41.0 ( )
18-mo PFS, % (95% CI)
23.4 ( )
NR, not reached; NSCLC, non-small-cell lung cancer; PD, progressive disease; SD, stable disease; TKI, tyrosine kinase inhibitor.
Slide credit: clinicaloptions.com
Solomon BJ, et al. ASCO Abstract 9009.

7. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Efficacy II
Lorlatinib RP2D of 100 mg QD achieved plasma concentrations sufficient to inhibit WT ALK and ROS1 fusions and in range to inhibit common secondary mutations
Demonstrated good CSF penetration and clinically significant intracranial responses
39% ORR in ALK+ pts with intracranial target lesions
Majority of ALK+, ROS1+ pts showed reduction in target lesion size with durable responses
20 of 41 ALK+ patients remain on treatment including 9 pts for longer than 1 yr
CSF, cerebrospinal fluid; NSCLC, non-small-cell lung cancer; RP2D, recommended phase II dose.
Slide credit: clinicaloptions.com
Solomon BJ, et al. ASCO Abstract 9009.

8. Lorlatinib in Advanced ALK+ or ROS1+ NSCLC: Conclusions
Lorlatinib well tolerated at RP2D of 100 mg QD with manageable toxicity profile
Hypercholesterolemia observed most frequently
Lorlatinib shows promising antitumor activity, including intracranial activity, in ALK+ and ROS1+ NSCLC pts pretreated with 1 or more approved ALK TKIs
Phase II portion of this trial currently under way
NSCLC, non-small-cell lung cancer; RP2D, recommended phase II dose; TKI, tyrosine kinase inhibitor.
Slide credit: clinicaloptions.com
Solomon BJ, et al. ASCO Abstract 9009.

9. Go Online for More CCO Coverage of ASCO 2016!
Short slideset summaries of all the key data
Additional CME-certified analyses with expert faculty commentary on all the key studies in:
Breast, genitourinary, and lung cancers
Hematologic malignancies
Immunotherapy
clinicaloptions.com/oncology